Latest news with #WAF
Yahoo
16 hours ago
- Business
- Yahoo
North America Web Application Firewall Market Forecast Report 2025-2033, with Key Player Profiles for Akamai Technologies, Cloudflare, Qualys, F5, Fortinet, Radware, Microsoft & Barracuda Networks
As threats evolve, businesses across industries are investing heavily in WAF solutions to protect digital assets, ensure regulatory compliance, and maintain customer trust. Cloud-hosted WAF products offer scalability and easy deployment, spurring adoption. Key sectors include e-commerce, healthcare, and finance. Challenges persist in high implementation costs and integration with legacy systems. North American Web Application Firewall Market Dublin, June 09, 2025 (GLOBE NEWSWIRE) -- The "North America Web Application Firewall Market Size and Growth Trends and Forecast Report 2025-2033" report has been added to North America Web Application Firewall (WAF) Market is expected to expand strongly, increasing from USD 2.13 billion in 2024 to USD 6.65 billion by 2033. The growth is driven by growing cybersecurity threats, an upsurge in web-based applications, and strict data protection laws. Companies across industries are spending big on WAF solutions to protect digital assets, provide regulatory compliance, and preserve customer trust. Growth Drivers in the Web Application Firewall Market in North America Increased Cybersecurity ThreatsIncreased levels and frequency of cyberattacks have hugely driven up the uptake of Web Application Firewalls (WAFs) in North America. Organizations are constantly threatened by ransomware, phishing, and DDoS attacks on their web applications. WAFs offer essential protection by blocking malicious traffic and guarding against data breaches. With an increasing number of businesses migrating more services online, protecting customer data and business data has become more pressing, and WAF adoption across industries has been growing widespread. May 2023, Global cybersecurity software and services company Fortra unveiled an upgraded Managed Web Application Firewall (WAF) service. Offered by Fortra's Alert Logic business, the solution integrates the sophisticated tools and security know-how organizations require to safeguard key web applications and APIs from attack.E-commerce and Digital Services GrowthThe proliferation of online retailing, digital banking, and telemedicine services has driven the demand for solid web application security. As companies expand their online platforms, so too does the attack surface, leaving them increasingly exposed. WAFs secure customer transactions and sensitive data, maintain business continuity and compliance, and support regulatory mandates. The growing need for safe and seamless online experiences is forcing North American businesses to spend generously on sophisticated WAF solutions. Feb 2025, Yottaa, a pioneer in eCommerce website performance optimization, introduced Yottaa Web Performance Services. This managed solution accelerates website performance, increases security, and reduces operational complexity for online retailers and brands. Leverage best-in-class technologies from Fastly, HUMAN Security, and Yottaa, it delivers a high-performance platform optimized for Data Protection RegulationsRegulations such as the California Consumer Privacy Act (CCPA) and vertical regulations such as HIPAA have imposed strict data protection requirements. Firms must protect personal and financial data or incur massive fines. WAFs are important components in compliance initiatives by protecting web applications from unauthorized access and security breaches. The regulatory landscape in North America is driving organizations in various industries - particularly healthcare, finance, and retail - to invest in WAF as a means of evading legal consequences. The California Privacy Rights Act (CPRA), enacted through ballot initiative in November 2020, is the most far-reaching state data privacy law to date. It modifies the California Consumer Privacy Act (CCPA) and became effective in January in the North America Web Application Firewall Market High Implementation and Maintenance CostsIt is costly to implement and manage WAF solutions, particularly in small and medium-sized enterprises (SMBs). The costs consist of software licenses, hardware appliances, professional IT personnel, and maintenance. Such costs might drive most organizations away from investing in high-quality WAF systems, especially when matching limited cybersecurity budgets. Moreover, regular updates and tuning must be done to ensure that WAFs remain effective, and this contributes to the overall cost of ownership and represents a serious market Integration with Legacy SystemsMost North American businesses have legacy IT infrastructure. It is complex and expensive to integrate newer WAF solutions with older systems. Integration can lead to compatibility problems, poor system performance, and rising operation risks. The complexity tends to hinder or slow down WAF deployment, particularly in traditional sectors such as manufacturing and government, and thus brakes the overall expansion of the WAF market across North States Web Application Firewall MarketThe United States leads the North America WAF market due to a widespread presence of healthcare organizations, financial institutions, and tech giants. High WAF adoption rates are being driven by stringent regulatory standards, increasing cybersecurity threats, and operational resilience demands. U.S. firms are making investments in both cloud and on-premises WAF products to protect their assets from sophisticated threats and also remain compliant with federal and state data protection legislation. March 2025, Akamai Technologies, Inc. has been identified as a Leader in The Forrester Wave: Web Application Firewall Solutions, Q1 2025 Web Application Firewall MarketCanada's WAF market is steadily developing, with momentum provided by measures to strengthen country-level cybersecurity capabilities and defend sensitive infrastructure. Enterprise adoption of digital services in Canada is growing fast, which ranks cybersecurity high as a concern. Banking, health, and the government are industries that lead in WAF consumption. Beyond defenses against data intrusions, Canada's WAFs enable entities to comply with privacy regulations such as PIPEDA. June 2024: Vercara is opening its first distributed denial-of-service (DDoS) and application security (AppSec) point of presence (PoP) in Toronto, Canada. The new PoP expands Vercara's international presence for its UltraDDoS Protect and UltraWAF solutions, providing Canadian customers with an in-country data processing and mitigation Web Application Firewall MarketMexico's WAF market is growing as companies go digital and face an increasing number of cyber attacks. Sectors like finance, retail, and manufacturing are prioritizing web application security to safeguard consumer information and business processes. While awareness of cybersecurity has increased, market issues persist in terms of cost and technical skills. Nevertheless, growing investments in IT security and government initiatives are driving WAF adoption in the country. Key Players Analysis Akamai Technologies, Inc. Cloudflare Inc. Qualys Inc. F5 Inc. Fortinet Inc. Radware Ltd. Microsoft Corporation Barracuda Networks, Inc. Key Attributes: Report Attribute Details No. of Pages 200 Forecast Period 2024 - 2033 Estimated Market Value (USD) in 2024 $2.13 Billion Forecasted Market Value (USD) by 2033 $6.65 Billion Compound Annual Growth Rate 13.5% Regions Covered North America North America Web Application Firewall Market Segmentation Component Solution Services Organization Type Large Enterprises Small and Medium Enterprises Deployment Mode On-Premise Cloud Industry Vertical Retail BFSI Manufacturing Government IT & Telecommunication Healthcare Energy & Utilities Others Countries United States Canada Mexico Rest of North America The key players have been analyzed by: Overviews Key Persons Recent Developments Revenue For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment North American Web Application Firewall Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Yahoo
6 days ago
- General
- Yahoo
It's not personal, but the DMV H8s your latest efforts
LAS VEGAS (KLAS) — The Nevada DMV rejected a personalized license plate in February when someone with a Woman Veteran specialty plate asked for 'WAF' — presumably, a salute to the Women's Air Force program that ran from 1948 to 1976. The DMV reasoned that 'WAF' might stand for 'weird as f***.' That was just one among the 1,054 decisions issued by the Department of Motor Vehicles from April 24 to the end of March 2025. Most were clearly attempts to sneak phrases past the people who screen requests for personalized plates. 2023 LIST: See the license plates the Nevada DMV rejected in 2022 The DMV denied 885 requests and approved 120, including some 'with restrictions.' The DMV couldn't decide without a tiebreaking vote on five requests: YEETIT (denied) HIGGS B (approved GPASMF (denied) DNGRSS (approved) FP2WDW (approved) And 35 plates were recalled after they were initially issued. Among those: 10 plates deemed confusing to law enforcement because of repeated numbers that made them hard to read. Nevadans showed their creativity in coming up with those special plates. The DMV identified plates that fall into categories seen as vulgar, racist, sexual and gang-related, among others. They even stopped some plates because they were perceived references to British slang, Portuguese slang and gay men's slang. Plates with '69' were rejected as sexual references; '88' was flagged as a Nazi reference. 2022 LIST: Custom license plates approved and rejected by Nevada's DMV We have broken the list into smaller pieces below, each with their own theme. We have tried to obscure profanity and vulgar language, and we want to say thank you to anyone who's making that effort to put a license plate on their vehicle. Angry much? It's crazy the things people want to put on their license plates. Here are 73 personalized plates that went before the DMV judges from April 2024 to the end of March 2025: Cute-sexy works, but most of these 254 tries crossed the line: Profane or vulgar references were turned away almost every time, with 338 requests hitting this wall. People are sure to keep trying to get them past the DMV: Drug-related references will get your personalized plate denied, even if you don't realize you've done it. Those references aren't the type of fun DMV wants to see. Here are 62 examples: 'Gang-related' covers a lot of ground for the DMV, which put 168 requests in this category. Anything that has even a hint of a connection of support for Nazis falls here. Sometimes, just a 'G' in the request for a personalized plate will be seen as 'gangster,' and 'OG' isn't likely to slide: Some people like to repeat letters or numbers. It might not be their intention, but those license plates can be difficult for police or first responders to read quickly when there's a need. Here are some examples (93), along with cases in which the DMV said the plate would have made it unclear if it might be a police vehicle: So whether you're an Elon hater (ELONSUX) or you're just asleep at the wheel (ZZZZ3), good luck next time with your request. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
National Post
29-04-2025
- Business
- National Post
Ability Biotherapeutics Moves to Inspire Bio Innovations in Montreal, Pioneering the New Generation of Targeted Antibodies
Article content MONTREAL — Ability Biotherapeutics, a Quebec-based leader in antibody therapeutics, is proud to announce its new location at Inspire Bio Innovations. The company will occupy the 6th floor of Phase 2 in the transformative redevelopment of the former Montreal Chest Institute, marking a significant step in its growth within Montreal's thriving life sciences ecosystem. Article content Article content The project's first phase is scheduled for completion this summer, with the second phase, including Ability's new space, expected to wrap up by the end of 2026. Ability Biotherapeutics is pioneering a new generation of targeted antibody therapies for cancer and autoimmune diseases, powered by its proprietary generative AI-based AbiLeap™ platform. Ability is advancing multiple drug discovery programs, with three lead programs now entering optimization and development as it prepares for preclinical studies. Taking advantage of Inspire Bio Innovations' dynamic environment, Ability plans to complete preclinical studies to demonstrate the effectiveness of its therapeutic products and to begin large-scale production in preparation for the first human clinical trials. These steps are expected to enable the company to triple its number of employees by 2028. Article content Since its unveiling less than two years ago, the Inspire project has sparked genuine enthusiasm within the life sciences ecosystem. Initially hosting the headquarters of Cellcarta, it has since brought together various Montreal universities and the Montreal Clinical Research Institute (IRCM). The project gained international recognition by being awarded the title of Future Office Project of the Year at the prestigious World Architecture Festival (WAF). This life sciences hub is already attracting a community of forward-thinking researchers and entrepreneurs focused on innovation, and continues to welcome companies from around the world seeking to thrive in its dynamic environment. Article content Located in the heart of downtown Montreal, Inspire Bio Innovations offers an ideal location with easy access via public and active transportation and proximity to major highways. This life sciences innovation hub is strategically located near a vibrant community of research centres and top-tier researchers, including MILA, CR-CHUM, CR-CUSUM, IRCM, and IRIC. This proximity will significantly enhance interactions and knowledge sharing. Additionally, being close to major hospitals like CHUM and MUHC will streamline the execution of local clinical studies. These factors make Inspire Bio Innovations highly attractive for retaining current talent and recruiting global experts. Article content 'We are excited to pursue our activities within Inspire Bio Innovations, a cutting-edge hub that fosters exchanges and interactions with top-tier researchers and innovative entrepreneurs. The collaborative environment created by Jadco is ideal for advancing the development of therapies with the potential to transform the treatment of patients with cancer or autoimmune diseases, both in Québec and globally.'—Patrick Tremblay, Ph.D., Chief Operating Officer at Ability Biotherapeutics. Article content 'We firmly believe that Inspire Bio Innovations is the ideal hub for nurturing the next generation of researchers and innovators who will propel the entire life sciences ecosystem forward. Montreal possesses all the attributes necessary to strengthen its role as one of the most dynamic and promising international centres in this field. This new space, dedicated to innovation and precision medicine, will unite talented teams whose work will continue this tradition while facilitating the commercialization of discoveries.'—Normand Rivard, Managing Partner, Life Sciences and Innovation, Jadco Group. Article content 'Ability Biotherapeutics' addition to the Inspire Bio Innovations scientific hub once again demonstrates the excellence of this innovation centre dedicated to scientific research. This new partnership strengthens the project's leading role in biotechnology. We are delighted to see this promising collaboration take shape in Plateau-Mont-Royal.'—Luc Rabouin, Leader of Projet Montréal. Article content About Ability Biotherapeutics Ability Biotherapeutics is the next-generation biotherapeutics company developing logic-gated antibodies with exceptional contextual selectivity and stability, driving safer, more effective immunotherapies for cancer and autoimmune diseases. Its proprietary platform, AbiLeap™, uses generative AI powered by one of the largest and exclusively held, therapeutically relevant human antibody databases, providing distinct insights for sequence space exploration. Combining AI with in vitro display and screening technologies, AbiLeap™ generates fully human antibodies that are conditionally activated and multi-specific, directing therapeutic targeting to specific cells and disease sites. This approach enables solutions for indications with high unmet clinical needs by reducing toxicity and significantly broadening the therapeutic window, maximizing treatment benefits. Ability's experienced team is committed to revolutionizing targeted therapeutics to transform patient outcomes and redefine industry standards. Article content Article content Article content Article content Article content Contacts Article content Article content Article content
Yahoo
29-04-2025
- Business
- Yahoo
Ability Biotherapeutics Moves to Inspire Bio Innovations in Montreal, Pioneering the New Generation of Targeted Antibodies
MONTREAL, April 29, 2025--(BUSINESS WIRE)--Ability Biotherapeutics, a Quebec-based leader in antibody therapeutics, is proud to announce its new location at Inspire Bio Innovations. The company will occupy the 6th floor of Phase 2 in the transformative redevelopment of the former Montreal Chest Institute, marking a significant step in its growth within Montreal's thriving life sciences ecosystem. The project's first phase is scheduled for completion this summer, with the second phase, including Ability's new space, expected to wrap up by the end of 2026. Ability Biotherapeutics is pioneering a new generation of targeted antibody therapies for cancer and autoimmune diseases, powered by its proprietary generative AI-based AbiLeap™ platform. Ability is advancing multiple drug discovery programs, with three lead programs now entering optimization and development as it prepares for preclinical studies. Taking advantage of Inspire Bio Innovations' dynamic environment, Ability plans to complete preclinical studies to demonstrate the effectiveness of its therapeutic products and to begin large-scale production in preparation for the first human clinical trials. These steps are expected to enable the company to triple its number of employees by 2028. Since its unveiling less than two years ago, the Inspire project has sparked genuine enthusiasm within the life sciences ecosystem. Initially hosting the headquarters of Cellcarta, it has since brought together various Montreal universities and the Montreal Clinical Research Institute (IRCM). The project gained international recognition by being awarded the title of Future Office Project of the Year at the prestigious World Architecture Festival (WAF). This life sciences hub is already attracting a community of forward-thinking researchers and entrepreneurs focused on innovation, and continues to welcome companies from around the world seeking to thrive in its dynamic environment. Located in the heart of downtown Montreal, Inspire Bio Innovations offers an ideal location with easy access via public and active transportation and proximity to major highways. This life sciences innovation hub is strategically located near a vibrant community of research centres and top-tier researchers, including MILA, CR-CHUM, CR-CUSUM, IRCM, and IRIC. This proximity will significantly enhance interactions and knowledge sharing. Additionally, being close to major hospitals like CHUM and MUHC will streamline the execution of local clinical studies. These factors make Inspire Bio Innovations highly attractive for retaining current talent and recruiting global experts. Quotes "We are excited to pursue our activities within Inspire Bio Innovations, a cutting-edge hub that fosters exchanges and interactions with top-tier researchers and innovative entrepreneurs. The collaborative environment created by Jadco is ideal for advancing the development of therapies with the potential to transform the treatment of patients with cancer or autoimmune diseases, both in Québec and globally."—Patrick Tremblay, Ph.D., Chief Operating Officer at Ability Biotherapeutics. "We firmly believe that Inspire Bio Innovations is the ideal hub for nurturing the next generation of researchers and innovators who will propel the entire life sciences ecosystem forward. Montreal possesses all the attributes necessary to strengthen its role as one of the most dynamic and promising international centres in this field. This new space, dedicated to innovation and precision medicine, will unite talented teams whose work will continue this tradition while facilitating the commercialization of discoveries."—Normand Rivard, Managing Partner, Life Sciences and Innovation, Jadco Group. "Ability Biotherapeutics' addition to the Inspire Bio Innovations scientific hub once again demonstrates the excellence of this innovation centre dedicated to scientific research. This new partnership strengthens the project's leading role in biotechnology. We are delighted to see this promising collaboration take shape in Plateau-Mont-Royal."—Luc Rabouin, Leader of Projet Montréal. About Ability BiotherapeuticsAbility Biotherapeutics is the next-generation biotherapeutics company developing logic-gated antibodies with exceptional contextual selectivity and stability, driving safer, more effective immunotherapies for cancer and autoimmune diseases. Its proprietary platform, AbiLeap™, uses generative AI powered by one of the largest and exclusively held, therapeutically relevant human antibody databases, providing distinct insights for sequence space exploration. Combining AI with in vitro display and screening technologies, AbiLeap™ generates fully human antibodies that are conditionally activated and multi-specific, directing therapeutic targeting to specific cells and disease sites. This approach enables solutions for indications with high unmet clinical needs by reducing toxicity and significantly broadening the therapeutic window, maximizing treatment benefits. Ability's experienced team is committed to revolutionizing targeted therapeutics to transform patient outcomes and redefine industry standards. About Jadco GroupFounded in 1987, Jadco Group is a Quebec-based real estate company that designs, develops and builds signature residential and industrial projects specifically for the life sciences ecosystem. Renowned for the high quality of its projects, which meet the most stringent ESG standards, Jadco and its institutional partners have accumulated over $1.2 billion in investments in Québec. The company also acts as a property manager. View source version on Contacts Information and interviews: Stéphanie BilodeauCommunication AdvisorAbility Biotherapeuticsstephanie@ Sign in to access your portfolio
Associated Press
29-04-2025
- Business
- Associated Press
Ability Biotherapeutics Moves to Inspire Bio Innovations in Montreal, Pioneering the New Generation of Targeted Antibodies
MONTREAL--(BUSINESS WIRE)--Apr 29, 2025-- Ability Biotherapeutics, a Quebec-based leader in antibody therapeutics, is proud to announce its new location at Inspire Bio Innovations. The company will occupy the 6th floor of Phase 2 in the transformative redevelopment of the former Montreal Chest Institute, marking a significant step in its growth within Montreal's thriving life sciences ecosystem. The project's first phase is scheduled for completion this summer, with the second phase, including Ability's new space, expected to wrap up by the end of 2026. Ability Biotherapeutics is pioneering a new generation of targeted antibody therapies for cancer and autoimmune diseases, powered by its proprietary generative AI-based AbiLeap™ platform. Ability is advancing multiple drug discovery programs, with three lead programs now entering optimization and development as it prepares for preclinical studies. Taking advantage of Inspire Bio Innovations' dynamic environment, Ability plans to complete preclinical studies to demonstrate the effectiveness of its therapeutic products and to begin large-scale production in preparation for the first human clinical trials. These steps are expected to enable the company to triple its number of employees by 2028. Since its unveiling less than two years ago, the Inspire project has sparked genuine enthusiasm within the life sciences ecosystem. Initially hosting the headquarters of Cellcarta, it has since brought together various Montreal universities and the Montreal Clinical Research Institute (IRCM). The project gained international recognition by being awarded the title of Future Office Project of the Year at the prestigious World Architecture Festival (WAF). This life sciences hub is already attracting a community of forward-thinking researchers and entrepreneurs focused on innovation, and continues to welcome companies from around the world seeking to thrive in its dynamic environment. Located in the heart of downtown Montreal, Inspire Bio Innovations offers an ideal location with easy access via public and active transportation and proximity to major highways. This life sciences innovation hub is strategically located near a vibrant community of research centres and top-tier researchers, including MILA, CR-CHUM, CR-CUSUM, IRCM, and IRIC. This proximity will significantly enhance interactions and knowledge sharing. Additionally, being close to major hospitals like CHUM and MUHC will streamline the execution of local clinical studies. These factors make Inspire Bio Innovations highly attractive for retaining current talent and recruiting global experts. Quotes 'We are excited to pursue our activities within Inspire Bio Innovations, a cutting-edge hub that fosters exchanges and interactions with top-tier researchers and innovative entrepreneurs. The collaborative environment created by Jadco is ideal for advancing the development of therapies with the potential to transform the treatment of patients with cancer or autoimmune diseases, both in Québec and globally.'—Patrick Tremblay, Ph.D., Chief Operating Officer at Ability Biotherapeutics. 'We firmly believe that Inspire Bio Innovations is the ideal hub for nurturing the next generation of researchers and innovators who will propel the entire life sciences ecosystem forward. Montreal possesses all the attributes necessary to strengthen its role as one of the most dynamic and promising international centres in this field. This new space, dedicated to innovation and precision medicine, will unite talented teams whose work will continue this tradition while facilitating the commercialization of discoveries.'—Normand Rivard, Managing Partner, Life Sciences and Innovation, Jadco Group. 'Ability Biotherapeutics' addition to the Inspire Bio Innovations scientific hub once again demonstrates the excellence of this innovation centre dedicated to scientific research. This new partnership strengthens the project's leading role in biotechnology. We are delighted to see this promising collaboration take shape in Plateau-Mont-Royal.'—Luc Rabouin, Leader of Projet Montréal. View source version on CONTACT: Information and interviews: Stéphanie Bilodeau Communication Advisor Ability Biotherapeutics [email protected] KEYWORD: NORTH AMERICA CANADA INDUSTRY KEYWORD: ONCOLOGY HEALTH TECHNOLOGY HEALTH TECHNOLOGY ARTIFICIAL INTELLIGENCE BIOTECHNOLOGY SOURCE: Ability Biotherapeutics Copyright Business Wire 2025. PUB: 04/29/2025 07:45 AM/DISC: 04/29/2025 07:44 AM
